

1 **TITLE PAGE**

2

3 **Title:** Predicting future ocular *Chlamydia trachomatis* infection prevalence using serological,
4 clinical, molecular, and geospatial data

5

6 **Authors:** Christine Tedijanto¹, Solomon Aragie², Zerihun Tadesse², Mahteme Haile³, Taye
7 Zeru³, Scott D. Nash⁴, Dionna M. Wittberg¹, Sarah Gwyn⁵, Diana L. Martin⁵, Hugh J.W.
8 Sturrock⁶, Thomas M. Lietman^{1,7,8,9}, Jeremy D. Keenan^{1,7}, Benjamin F. Arnold^{1,7}

9

10 **Author affiliations:** ¹Francis I. Proctor Foundation, University of California, San Francisco, CA
11 94143; ²The Carter Center Ethiopia, Addis Ababa, Ethiopia; ³Amhara Public Health Institute,
12 Bahir Dar, Ethiopia; ⁴The Carter Center, Atlanta, Georgia; ⁵Division of Parasitic Diseases and
13 Malaria, Centers for Disease Control and Prevention, Atlanta, GA 30333; ⁶Locational, Poole,
14 UK; ⁷Department of Ophthalmology, University of California, San Francisco, CA 94143;
15 ⁸Department of Epidemiology and Biostatistics, University of California, San Francisco, CA
16 94143; ⁹Institute for Global Health Sciences, University of California, San Francisco, CA 94143;

17

18 **Corresponding author:** Christine Tedijanto

19 *Email:* christine.tedijanto@ucsf.edu

20 *Address:* F.I. Proctor Foundation, 490 Illinois Street, San Francisco, CA 94107

21

22 **Keywords:** trachoma, epidemiology, serology, prediction, geospatial

23 **ABSTRACT**

24
25 Trachoma is an infectious disease characterized by repeated exposures to *Chlamydia*
26 *trachomatis* (Ct) that may ultimately lead to blindness. District-level estimates of clinical disease
27 are currently used to guide control programs. However, clinical trachoma is a subjective
28 indicator. Serological markers present an objective, scalable alternative for monitoring and
29 targeting of more intensive control efforts. We hypothesized that IgG seroprevalence in
30 combination with geospatial layers, machine learning, and model-based geostatistics would be
31 able to accurately predict future community-level ocular Ct infections detected by PCR. Among
32 40 communities in the hyperendemic Amhara region of Ethiopia, median Ct infection prevalence
33 among children 0-5 years old increased from 6% at enrollment to 29% at month 36.
34 Seroprevalence was the strongest concurrent predictor of infection prevalence at month 36
35 among children 0-5 years old (cross-validated $R^2 = 0.75$, 95% CI: 0.58-0.85), though predictive
36 performance declined substantially with increasing temporal lag between predictor and outcome
37 measurements. Geospatial variables, a spatial Gaussian process, and stacked ensemble
38 machine learning did not meaningfully improve predictions. Serological markers among children
39 0-5 years old may be a promising programmatic tool for identifying communities with high levels
40 of active ocular Ct infections, but accurate, future prediction in the context of changing
41 transmission remains a challenge.

42 43 **INTRODUCTION**

44
45 Trachoma, caused by ocular infection with the bacterium *Chlamydia trachomatis* (Ct), is a
46 leading infectious cause of blindness worldwide (1) and has been targeted for elimination as a
47 public health problem by 2030 (2). The World Health Organization's SAFE strategy (Surgery,
48 Antibiotics, Facial cleanliness, and Environmental improvement) has been successful in
49 countries across Asia and the Middle East, achieving elimination as a public health problem in
50 many cases (2). Yet, trachoma is a persistent challenge in pockets of Africa, including some
51 areas of Ethiopia that remain hyperendemic despite over 10 years of control activities (3). The
52 ability to efficiently identify potential areas of ongoing transmission for follow-up surveys and
53 more intensive interventions is crucial for the trachoma endgame.

54
55 Trachoma elimination programs are currently guided by estimates of clinical disease markers,
56 including trachomatous inflammation — follicular (TF), in evaluation units (EUs) of 100,000-
57 250,000 people (4). Evidence of trachoma clusters at the village- or sub-village level throughout
58 Africa (5–10) suggest that aggregate estimates may mask heterogeneity in infection: high-
59 transmission villages may be missed by sampling design or their signal may be “washed out” in
60 EU-level averages. Fine-scale estimates of trachoma could facilitate targeted allocation of
61 limited resources to communities with the highest burden (11) and reduce unnecessary
62 antibiotic use and subsequent selection for antibiotic resistance (12).

63
64 Mass drug administration (MDA) of azithromycin is currently recommended for EUs with TF
65 prevalence above 5% among children aged 1-9 years old (2). Clinical disease states are
66 relevant signals of progression towards conjunctival scarring and ultimately blindness (1) but are

67 subject to misclassification, even by experienced graders (13). Immunoglobulin G (IgG)
68 antibody responses to Pgp3 and CT694 antigens are a more objective alternative and have
69 been identified as sensitive, specific, and durable indicators of past ocular *Ct* infection (14, 15).
70 In addition, dried blood spot specimens used to assess serological markers are easy to collect,
71 and *Ct* antigens can be included in multiplexed, integrated serosurveillance platforms to
72 simultaneously and cost-effectively monitor numerous pathogens (16).

73

74 Thus far, efforts to predict future trachoma prevalence at the village and district level have had
75 modest success (17, 18) but have not considered serology or recent advances in machine
76 learning and geostatistics that may facilitate fine-scale prediction. We hypothesized that models
77 incorporating trachoma indicators (clinical disease, ocular *Ct* infection identified by polymerase
78 chain reaction (PCR), and IgG response to *Ct* antigens), remotely sensed geospatial layers, and
79 spatial structure would accurately predict future community-level *Ct* infection prevalence. We
80 also hypothesized that seroprevalence would be a more accurate and stable predictor of *Ct*
81 infections compared to clinical disease and that communities with high levels of infection would
82 be geographically clustered in stable foci of transmission (“hotspots”). We tested our
83 hypotheses using data from the WASH Upgrades for Health in Amhara (WUHA) randomized
84 controlled trial ([NCT02754583](https://clinicaltrials.gov/ct2/show/study/NCT02754583)) (19).


85

86 RESULTS

87

88 ***Study population and setting.*** WUHA was a randomized controlled trial designed to evaluate
89 the impact of a comprehensive water, sanitation, and hygiene (WASH) intervention on ocular *Ct*
90 infection. The trial was conducted in forty communities in a dry, mountainous region of the Wag
91 Hemra Zone of Amhara, Ethiopia (**Figure 1**). MDA was conducted for seven consecutive years
92 in the study communities before the study began but was suspended for the duration of the trial.
93 Baseline measurements were collected in December 2015 (month 0), and follow-up visits
94 occurred annually for three years thereafter (months 12, 24, and 36). Clinical, serological, and
95 molecular trachoma indicators were measured among randomly sampled children ages 0-9
96 years old at each visit. Data were combined across the two intervention arms for this secondary
97 analysis as no difference was observed for the primary endpoint of ocular *Ct* infection at the end
98 of the study period [manuscript under review].

99 **Figure 1. Map of study area.** Inset (top right) highlights the Amhara Region (gray shading) of Ethiopia
100 and the study area (black rectangle). Forty communities from three woredas (administrative level 3) in
101 Amhara were included in the WUHA trial.
102



103
104
105 Approximately thirty children from two age groups (0-5 years old and 6-9 years old) were
106 randomly sampled from each community at baseline and follow-up visits. The number of
107 children evaluated differed slightly for each trachoma indicator (**Table S1**). Over the three-year
108 study period, ocular *Ct* infection prevalence, as measured by PCR, increased substantially in
109 both age groups (**Table 1**). Throughout this analysis, clinical disease was defined as diagnosis
110 with either trachoma inflammation - follicular (TF), the presence of five or more follicles on the
111 upper eyelid, or trachoma inflammation - intense (TI), a condition characterized by inflammatory
112 thickening of the upper eyelid (20). Levels of clinical disease fluctuated with time but remained
113 fairly consistent with baseline levels. Seropositivity, defined as antibody response above pre-
114 determined cut-offs for both Pgp3 and CT694 antigens, increased gradually among 0–5-year-
115 olds. Antibodies were not measured among 6–9-year-olds at months 12 and 24 but were similar
116 between study arms at months 0 and 36. Results were similar when seroprevalence was
117 assessed for each antigen separately (**Table S2**).

118 **Table 1. Community-level prevalence of trachoma across 40 study communities by indicator, age**
119 **group and month of follow-up visit.**
120

Month	Median prevalence (%) (IQR), 0–5-year-olds				Median prevalence (%) (IQR), 6–9-year-olds			
	n ¹	PCR ²	Clinical TF/TI ³	Serology	n ¹	PCR ²	Clinical TF/TI ³	Serology ⁴
0	1,269	5.6 (2.9-18.1)	62.9 (51.0-72.5)	25.0 (10.1-34.8)	1,135	3.5 (0.0-13.9)	40.3 (25.9-54.9)	49.2 (29.8-60.2)
12	1,162	19.1 (6.6-30.2)	50.8 (40.6-61.1)	29.7 (15.6-40.2)	1,092	10.9 (5.7-17.4)	21.3 (14.3-27.8)	-
24	1,214	27.4 (11.6-34.3)	67.5 (55.5-77.4)	33.3 (20.5-39.0)	1,208	19.9 (9.7-34.2)	45.1 (29.4-53.4)	-
36	1,192	29.3 (16.2-46.8)	56.7 (45.2-64.3)	33.3 (23.5-42.3)	1,218	21.7 (15.2-38.2)	38.2 (30.1-53.6)	50.8 (28.9-65.4)

121 ¹ Number of children tested for any indicator across all study communities

122 ² Polymerase chain reaction


123 ³ Trachomatous inflammation - follicular / trachomatous inflammation - intense

124 ⁴ Serology was not measured for a random sample of 6–9-year-olds at months 12 and 24

125

126 Active ocular infection was more common in the western and northern regions of the study area
127 (Figure 2A); seroprevalence and clinical disease were similarly distributed in space (Figure
128 S1A, Figure S2A). Based on empirical variograms (Figure 2B) and Moran's I (Figure 2C),
129 there was weak spatial structure in community-level Ct PCR prevalence that increased slightly
130 over the study period; serology and clinical indicators also did not display clear spatial structure
131 over the study area (Figure S1B-C, Figure S2B-C).

132 **Figure 2. (A) Predicted surface, (B) variograms, and (C) Moran's I for PCR-confirmed ocular *C.***
133 ***trachomatis* infection prevalence among 0–5-year-olds at each study month.** Maps display
134 prevalence for 40 study communities at each follow-up visit, spatially interpolated over the convex hull
135 using kriging. Variograms capture similarity between community-level prevalence measurements as a
136 function of distance between community pairs (in km), with smaller semivariance values representing
137 increased similarity. Exponential (magenta) and Matérn (green) models were fit to each empirical
138 variogram, and the effective range (dashed vertical line) is defined as the distance at which the fitted
139 model reaches 95% of the sill. The Monte Carlo envelope (gray shading) displays pointwise 95%
140 coverage of 1000 permutations, representing a null distribution. Moran's I was calculated over 1000
141 permutations (gray bars, with observed value represented by red line), and a permutation-based p-value
142 was calculated.




143

144 **Comparisons between serological, clinical, and molecular trachoma indicators.**
145 Seroprevalence demonstrated a stronger rank-preserving relationship, as measured by the
146 Spearman correlation, with contemporaneous PCR prevalence than clinical disease for both
147 age groups (**Figure 3A-B**). At baseline, immediately following seven years of MDA, the
148 correlations between trachoma indicators were more pronounced among younger children,
149 potentially reflecting lower transmission in the presence of MDA and saturation in
150 seroprevalence due to durable antibody responses among older children. In a longitudinal
151 cohort nested within the study, children who were seropositive at any survey were very likely to
152 be seropositive one year later (**Figure S4**). Similar saturation dynamics may be at play for
153 clinical trachoma, which has been shown to resolve slowly among children (21). By month 36,
154 when infections were higher across the study area (**Table 1**), correlations between trachoma
155 indicators were similar across age groups (**Figure 3A-B**). Rank-preserving relationships
156 between indicators at each time point and month 36 PCR prevalence were stronger for more
157 proximate measurements, and this increase was more pronounced for PCR compared to clinical
158 trachoma or serology (**Figure 3C**).

159

160 **Figure 3. Correlations between trachoma indicators by age group and over time.** Panels display
161 Spearman rank correlations between (A) community-level seroprevalence and PCR prevalence at study
162 months 0 and 36, (B) clinical trachoma prevalence and PCR prevalence at months 0 and 36, and (C)
163 PCR prevalence at month 36 and trachoma indicators measured at earlier months across 40 study
164 communities. Correlations are shown separately for 0–5-year-olds (green) and 6–9-year-olds (purple),
165 and 95% confidence intervals were estimated from 1000 bootstrap samples. Serology data was not
166 collected for a random sample of 6–9-year-olds at months 12 and 24.
167



168


169 **Concurrent and forward prediction of PCR prevalence.** We predicted community-level
 170 infection prevalence using a range of model specifications and conducted spatial 10-fold cross-
 171 validation (CV) with 15x15 km blocks (22) to assess predictive performance using CV R^2 and
 172 root-mean-square-error (RMSE) (details in **Materials and Methods**). **Figure 4** presents results
 173 for models predicting PCR prevalence at month 36. “Concurrent” predictions utilized trachoma
 174 indicators measured at month 36 and/or geospatial variables measured over the preceding year
 175 (2018), while “forward” predictions used covariates measured 12, 24, or 36 months in the past.
 176 Seroprevalence was the single strongest concurrent predictor of month 36 community-level
 177 PCR prevalence (CV R^2 : 0.75, 95% confidence interval (CI): 0.58-0.85, CV RMSE: 0.10),
 178 substantially outperforming clinical trachoma prevalence (CV R^2 : 0.37, 95% CI: 0.08-0.56, CV
 179 RMSE: 0.16) (**Figure 4**). When predicting 12 months into the future, all trachoma indicators
 180 performed moderately well, but predictive performance declined for longer time horizons across
 181 all model specifications. No model that we assessed had a CV R^2 significantly different from 0
 182 (equivalent to an intercept-only or mean-only model) when predicting PCR prevalence 24
 183 months or more into the future.

184

185 As anticipated by the weak spatial dependence in PCR prevalence (**Figure 2**), incorporation of
 186 a Gaussian process with a Matérn covariance function did not improve predictions. In addition,
 187 LASSO-selected geospatial features (night light radiance and daily precipitation averaged over
 188 the preceding 12 months) (**Figure S5**) and a stacked ensemble approach leveraging five base
 189 models did not meaningfully improve CV R^2 or CV RMSE compared to simpler models. Results
 190 were similar for models predicting PCR prevalence at each time point and pooled over all time
 191 points (**Figure S6**).

192

193 **Figure 4. Cross-validated R^2 for models predicting month 36 community-level PCR prevalence**
 194 **among 0–5-year-olds.** Cross-validated coefficient of determination (R^2), 95% influence-function-based
 195 confidence interval, and cross-validated root-mean-square error (RMSE, text label) are shown for each
 196 model specification. Logistic regression was used for all models with the exception of the stacked
 197 ensemble (gray). Blocks of size 15x15km were used for 10-fold spatial cross-validation.



*Includes 12-month precipitation and night light radiance as selected by LASSO


198

199 **Efficient identification of high-burden communities.** A complementary task to prediction is
200 identifying communities with the highest infection burden, defined here as the number of *Ct*
201 infections among 0–5-year-olds at a given time. To address variability in sample size, the
202 number of *Ct* infections in each community was scaled to represent a sample of 30 individuals.
203 At month 36, 80% of *Ct* infections were concentrated in just over half of the communities
204 (23/40), and ordering communities by cross-validated concurrent predictions using
205 seroprevalence identified infections more efficiently (i.e. in fewer communities, 25/40) than
206 ordering them by predictions using clinical trachoma (27/40) (**Figure 5**). Performance declined
207 when using predictors measured 12 months in the past, and communities ranked by predictors
208 measured 24 and 36 months in the past could not identify high-burden communities based on
209 PCR infections at month 36 better than chance. The distinction between models was greater at
210 month 0 when 80% of *Ct* infections were concentrated in just the top 15 of 40 (38%) of
211 communities (**Figure S9**).

212

213 **Figure 5. Cumulative proportion of *C. trachomatis* infections at month 36 identified by concurrent**
214 **and forward prediction models.** Dashed lines indicate the point at which the cumulative proportion of
215 identified *Ct* infections at month 36, scaled to represent a sample of 30 individuals per community,
216 surpassed 80%. The black line in each facet represents the optimal ordering of scaled PCR infections at
217 month 36. To simulate a null distribution, we estimated the cumulative proportion of infections identified
218 for 1000 random orderings of the 40 communities and plotted the 95% pointwise envelope (gray shading).
219 For concurrent and 24-month-forward predictions, models using serology only and PCR only,
220 respectively, performed equally well to a model using all trachoma indicators, geospatial features, a
221 Matérn covariance, and ensemble machine learning; vertical lines were offset slightly for visibility.

222



223

224

225 DISCUSSION

226

227 We conducted a comprehensive study of repeated cross-sectional measurements of clinical
228 trachoma, PCR-positive ocular *Ct* infections, and serological responses to *Ct* antigens over
229 three years in 40 communities in the hyperendemic Amhara region of Ethiopia. In the absence
230 of MDA during the study, active *Ct* infections surged and became increasingly dispersed across
231 study communities. Based on empirical variograms and Moran's I, we observed weak evidence
232 for global spatial clustering in trachoma indicators over the study region. Seroprevalence among
233 children 0-5 years old aligned closely with PCR prevalence measured at the same time,

234 highlighting the potential for serosurveillance as a monitoring tool that corresponds well with
235 levels of active infection and is potentially easier to measure (23). Predictive performance of all
236 models declined with increasing temporal lag between outcome and predictor measurements. In
237 this setting, remotely sensed demographic, socioeconomic, and environmental geospatial
238 layers, a spatial Gaussian process with Matérn covariance, and stacked ensemble machine
239 learning did not meaningfully improve predictive performance compared to models using only
240 trachoma indicators.

241
242 Identifying potential future trachoma hotspots is notoriously challenging and sometimes termed
243 “chasing ghosts” by trachoma programs (17). Our results underscore the difficulty of predicting
244 community-level *Ct* infection prevalence even a year into the future, at least in the context of
245 increasing transmission in the absence of MDA. Furthermore, our “forward prediction” models
246 were trained on infection outcomes from the desired prediction time point and thus were
247 potentially more optimistic than true “forecasting” models trained solely on historical data. Prior
248 efforts to forecast district-level TF (18) and village-level PCR prevalence (17) have explored
249 mechanistic and statistical models and observed modest performance, with one investigation
250 concluding that models with the highest uncertainty resulted in the best predictive performance
251 (17). It remains unclear why future prediction of trachoma presents such a difficult challenge,
252 though likely contributing factors include the stochasticity of rare events especially in near-
253 elimination settings (24), biological unknowns in the complex natural history of trachoma (25),
254 and the extended duration between survey measurements (often 6 months or greater). Models
255 for other neglected tropical diseases have achieved some success in future prediction at the
256 sub-district level, though often capitalizing on larger datasets. For example, a recent study
257 developed models with over 80% accuracy for prediction of *Schistosoma mansoni* persistent
258 hotspots (defined as failure of a village to reduce infection prevalence and/or intensity by
259 specific thresholds) up to two years in the future in the context of decreasing prevalence (26). In
260 a setting with fairly stable transmission, a sub-district-level study for visceral leishmaniasis
261 reported 85.7% coverage of four-month-ahead 25-75% prediction intervals for case counts (27).

262
263 Our investigation builds upon an existing body of work characterizing the dynamics between
264 clinical, serological, and molecular trachoma indicators. Reports at the district, village, and
265 individual level have established that relatively high levels of clinical trachoma or ocular
266 infections tend to correspond to higher seroprevalence and/or seroconversion rates (14, 28–31);
267 post-elimination settings have been of particular interest, with populations often displaying little
268 to no antibody response (15, 32–37). Our findings align with earlier studies that showed clinical
269 trachoma is more strongly correlated with infection prevalence in populations with ongoing
270 transmission compared to populations in which transmission has been suppressed by MDA
271 (38–40); also in agreement with prior findings, we observed that TI was slightly, but not
272 significantly, more closely correlated with infection prevalence compared to TF immediately
273 following MDA (**Figure S10**) (41). We additionally found that seroprevalence among children 0-9
274 years old was more closely aligned with infection prevalence than clinical trachoma in both
275 contexts. Moreover, we found that seroprevalence was more strongly correlated with PCR
276 prevalence among children 0-5 years old compared to children 6-9 years old, especially in the

277 context of recent MDA at month 0. This result supports a focus on children 0-5 years old as a
278 key sentinel population for trachoma serosurveillance.

279
280 In general, we did not observe strong evidence of global spatial autocorrelation for trachoma
281 indicators over the study region, though spatial structure in PCR prevalence appeared to
282 increase slightly over the study period. A prior analysis over the entire Amhara region reported
283 evidence of spatial autocorrelation in TF between villages within 25km bands (10), and another
284 study of TF and TI in Southern Sudan detected residual spatial structure between villages at
285 approximately 8 km, after adjusting for age, sex, rainfall, and land cover (42). A larger number of
286 existing studies have characterized spatial autocorrelation at a fairly small scale. Studies using
287 household-level information identified spatial clustering at less than 2 km for bacterial load (6,
288 9), ocular infection (8, 9), and clinical disease (43). Our ability to detect spatial structure may
289 have been limited by the geographic distribution of the communities, which was determined by
290 the main trial objectives rather than optimized for estimation of spatial model parameters, which
291 often requires points fairly close to one another (44). In our study, only 26 (out of 780) pairs of
292 study communities were within 5 km of one another leading to wide uncertainty at small ranges
293 and hindering our ability to assess fine-scale spatial clustering.

294
295 In addition to rainfall and land cover, studies have reported associations between clinical
296 trachoma and distance to water source (10, 45–47), temperature (7, 46, 48), altitude (46, 48–
297 51), markers of socioeconomic status (7, 10, 45, 47, 51, 52), and markers of personal or
298 household hygiene, such as facial cleanliness (7, 10, 45, 47, 52–59). Fewer studies have
299 examined *Ct* infections identified by PCR, but associations reported were generally similar (52,
300 59, 60). Using LASSO to down-select geospatial features, we included night light radiance
301 (often a proxy for socioeconomic activity (61)) and precipitation in prediction models. However,
302 these features were unable to predict infection prevalence better than an intercept-only model.
303 Predictive power of geospatial variables may have been limited by relative homogeneity across
304 the study area, and the relatively small number of communities likely limited the predictive
305 performance of all models.

306
307 Finally, our analysis focused on a hyperendemic region with increasing trachoma transmission
308 in the absence of MDA and may not generalize to lower transmission settings. Ethiopia's
309 Amhara region presents a particularly stubborn elimination challenge, as seven consecutive
310 years of MDA were unable to sustain control before the start of this study. It is unclear whether
311 prediction would be more or less challenging in the context of low transmission; we may expect
312 more predictability in a "steady state" environment, but stochasticity is also a defining
313 characteristic of near-elimination disease dynamics (24). As an additional sensitivity analysis,
314 we included survey month as a covariate to assess potential benefits of repeated sampling in
315 the context of changing transmission and found only a modest improvement in predictive
316 performance (**Figure S11**).

317
318 **Conclusions.** Serological markers among children 0-5 years old may be well-suited for
319 community-level trachoma monitoring given their objectivity, durability, relative ease of
320 collection, and strong correlation with ocular *Ct* infection prevalence. While seroprevalence and

321 clinical trachoma were both correlated with infection prevalence in the midst of high
322 transmission in the absence of MDA, only seroprevalence was strongly associated with
323 community-level infections in the context of suppressed transmission directly following MDA.
324 Accurate, future prediction of community-level *Ct* infection prevalence in settings with unstable
325 transmission remains an open challenge.

326

327 **MATERIALS AND METHODS**

328

329 **Data collection.** This work was designed as a secondary analysis of data from the WASH
330 Upgrades for Health in Amhara (WUHA) community-randomized trial, one of the trials in the
331 Sanitation, Water, and Instruction in Face-Washing for Trachoma (SWIFT) ([NCT02754583](https://doi.org/10.1186/1745-6215-10-1))
332 series. Details of study methodology and implementation are described in the published protocol
333 (19). WUHA was conducted in the Gazgibella, Sekota Zuria (i.e. Sekota) and Sekota Ketema
334 (i.e. Sekota town) woredas of the Wag Hemra Zone in Amhara, Ethiopia. Forty communities
335 were randomized in a 1:1 ratio to receive a comprehensive Water, Sanitation, and Hygiene
336 (WASH) package at baseline or at completion of the study. Mass administration of azithromycin
337 occurred for seven consecutive years (May 2009 to June 2015, with supplemental
338 administration in October 2014) prior to the start of the study but was suspended in all study
339 communities for the duration of the WUHA trial.

340

341 Trachoma indicators were measured in each study community at baseline and three annual
342 monitoring visits. Approximately one month prior to each monitoring visit, a census was taken to
343 enumerate individuals living in each study community. The baseline census was conducted in
344 December 2015. At each visit, thirty individuals in three age groups (0-5, 6-9, 10+) were
345 randomly selected from each community for monitoring; this analysis focused on children aged
346 0-9 years old. Per the trial design, not all trachoma indicators were measured in all age groups
347 at each time point; only children 0-5 years old were tested for clinical, serological, and molecular
348 outcomes at all visits. At the end of WUHA, no difference in the primary endpoint of community-
349 level ocular *Ct* infection among 0–5-year-olds was observed between intervention arms
350 [manuscript under review]. As a result, we combined information across arms for this analysis.

351

352 **Measurement and definition of trachoma indicators.** We analyzed age-group-specific
353 community-level prevalence of three trachoma indicators: clinical disease, active ocular *Ct*
354 infection detected by polymerase chain reaction (PCR), and IgG response to Pgp3 and CT694
355 antigens.

356

357 Trained trachoma graders used a pair of 2.5X loupes and a flashlight to assess the everted right
358 superior tarsal conjunctiva for the presence of trachomatous inflammation - follicular (TF) or
359 trachomatous inflammation - intense (TI) according to the WHO grading system (62). An
360 individual was considered positive for clinical trachoma if either TF or TI was detected.

361

362 Conjunctival swabs were collected and tested in the study laboratory at the Amhara Public
363 Health Institute in Bahir Dar, Ethiopia with the Abbott RealTime assay (automated Abbott
364 m2000 System), which is highly sensitive and specific for *Ct* (63, 64). Groups of five samples,

365 stratified by community and age group, were pooled for testing, and community-level *Ct*
366 infection prevalence was estimated from pooled results using a maximum likelihood approach
367 (65). Certain pools were selected for individual-level PCR testing based on pooled prevalence
368 and other characteristics.

369
370 To measure antibody response, field staff lanced the index finger of each individual and
371 collected blood onto TropBio filter paper. Samples were tested at the US Centers for Disease
372 Control on a multiplex bead assay on the Luminex platform for antibodies to two recombinant
373 antigens (Pgp3, CT694) that measure previous exposure to *C. trachomatis* (14, 15, 66).
374 Seropositivity thresholds were defined as median fluorescence intensity minus background
375 (MFI-bg) of 1113 for Pgp3 and 337 for CT694 using an ROC cutoff from reference samples (37).
376 Individuals who were seropositive with respect to both antigens were considered seropositive
377 for the main analysis; descriptive results were similar when considering either antigen
378 separately (**Table S2, Figure S3**). Descriptive analysis of trachoma indicators. Spearman rank
379 correlation coefficients were calculated for pairwise combinations of trachoma indicators by age
380 group and follow-up visit. Correlations were also calculated between PCR prevalence at month
381 36 and serological, molecular, and clinical prevalence at each preceding time point to observe
382 changes in correlation with increasing temporal lag between measurements. 95% confidence
383 intervals were estimated from 1000 bootstrap samples.

384
385 **Descriptive spatial analysis.** Administrative boundaries for Ethiopia were downloaded from the
386 Humanitarian Data Exchange (67). Spatially interpolated maps for each trachoma indicator at
387 each time point were generated using a simple kriging model including latitude, longitude, and a
388 Matérn covariance. We estimated empirical variograms after removing linear spatial trends for
389 distances up to 33.3 km (half of the maximum distance between any two study communities)
390 and fit exponential and Matérn models; for stability, we required bins to contain ten or more
391 pairs of communities. The effective, or practical, range was defined as the distance at which the
392 fitted model reached 95% of the sill. We compared the observed variograms to a 95% pointwise
393 envelope based on 1000 Monte Carlo simulations; for each simulation, prevalence residuals
394 were permuted while holding coordinates fixed and the empirical variogram was recalculated
395 (68). We also calculated Moran's I, a measure of global spatial autocorrelation, over 1000
396 permutations of the prevalence values and estimated a p-value based on permutations resulting
397 in a Moran's I greater than or equal to the observed value.

398
399 **Predictive model selection.** Prediction models were limited to children 0-5 years old due to
400 availability of all trachoma indicators for this age range at all time points. We developed several
401 candidate models using baseline data only, with the analysis team masked to any future
402 measurements. A wide range of publicly available environmental (69–73), demographic (74),
403 and socioeconomic (75–77) variables were explored based on prior associations with trachoma
404 or other infectious diseases (Table S3). When possible, features were extracted and aggregated
405 using Google Earth Engine (78), and means were used for spatial and temporal aggregation
406 unless otherwise specified in Table S3. All features were aggregated to a grid resolution of 2.5
407 arc minutes (approximately 4.5 km at the median latitude of the study area) based on the lowest
408 resolution dataset (TerraClimate) and reprojected to WGS84. Each community was assigned to

409 the grid cell containing its household-weighted geographic centroid, defined as the median
410 latitude and longitude across all households in the community.

411
412 Models were built using predictor variables measured over the same (“concurrent”) and prior
413 (“forward predictions”) time periods. Time-varying features were summarized based on calendar
414 year, with 2015 data considered “concurrent” with month 0 trachoma indicators and so on.
415 Time-varying features were first aggregated by month and then summarized based on recency
416 relative to the time of monitoring (e.g. last 1 month or December of the calendar year, last 2
417 months, up to 12 months). To reduce collinearity, we evaluated pairwise Pearson correlation
418 coefficients between temporal summaries of the same variable and dropped the summary over
419 fewer months for pairs with correlation over 0.9.

420
421 During preliminary model development with baseline data, we observed that a large number of
422 predictor variables led to overfitting and unstable model performance due to the relatively small
423 number of communities. As a result, logistic LASSO regression was used to identify a restricted
424 set of geospatial features to include in the final prediction models. Night light radiance and daily
425 precipitation averaged over the preceding 12 months were selected from a model using
426 concurrently measured predictors and outcomes across all follow-up visits.

427
428 Logistic regression models of the following form were used as base prediction models:
429

$$430 \quad \text{logit}(p_{cm}) = \alpha + \sum_p \beta_{np} x_{cnp} + S(\text{latitude}_c, \text{longitude}_c)$$

431
432 where p_{cm} represents PCR prevalence for study community c at month m , α is the model
433 intercept, and $x_{cn1} \dots x_{cnp}$ denote covariates with coefficients β measured at time n , where $n = m$
434 for concurrent predictions and $n = m - k$ for predictions k months forward. Extended models also
435 included a Gaussian process with Matérn covariance function (79) to capture residual spatial
436 structure, represented by the S function dependent on latitude and longitude of the community.

437
438 As an extension of our prediction models, we also explored stacked ensemble machine
439 learning, also known as stacked regression (80) or stacked generalization (81). Stacked
440 ensembles combine predictions from multiple ‘Level 0’ models using a ‘Level 1’ model, also
441 called the superlearner or metalearner (82). Ensembles are theoretically guaranteed to perform
442 as well as or better than any single member of their library (80, 82). Our ‘Level 0’ learners
443 included logistic regression, generalized additive models (83), random forest (84), extreme
444 gradient boosting (85), and multivariate adaptive regression splines (86). This set of models,
445 including parametric, semi-parametric, and tree-based methods, was selected to ensure
446 diversity in approach; outcome specification also varied (e.g. binomial, quasibinomial,
447 continuous) based on requirements of the learner. Logistic regression with a Matérn covariance
448 was used as ‘Level 1’ superlearner for the baseline analysis; different superlearner models,
449 including logistic regression without a Matérn covariance and non-negative linear least squares
450 with and without normalized (convex combination) coefficients, resulted in similar predictive
451 performance (**Figure S7**).

452

453 **Predictive model assessment.** We conducted 10-fold cross-validation to assess predictive
454 performance. Spatial autocorrelation can violate the independence assumption between training
455 and validation sets in cross-validation and lead to overly optimistic estimates of predictive power
456 (22, 87). Therefore, we partitioned the study area into 12 15x15km blocks, each containing 1-8
457 spatially proximate communities. Communities in the same block were assigned to the same
458 validation set, with some sets consisting of more than one block. This approach decreases
459 spatial dependence between training and validation sets in the same fold and simulates
460 prediction in a new, but geographically proximate, area. We observed consistent results in
461 sensitivity analyses using leave-one-out cross-validation, random cross-validation folds, and
462 spatial blocks of 5x5 km and 20x20 km (**Figure S8**), perhaps reflecting the weak spatial
463 autocorrelation observed in this dataset (**Figure 2**). Predictive performance was assessed using
464 cross-validated root-mean-square-error (RMSE) and R^2 (88), where R^2 was calculated as:
465

$$1 - \frac{\sum_c (p_{cm} - \hat{p}_{cm})^2}{\sum_c (p_{cm} - \bar{p}_{cm})^2}$$

466
467
468
469
470

95% confidence intervals for R^2 were estimated using the influence function (89, 90).
Communities received equal weight in all validation metrics.

471 **Acknowledgements and funding sources.** We would like to thank the WUHA study
472 participants and field team without whom this research would not be possible. This work was
473 supported by the National Institute of Allergy and Infectious Diseases (R03 AI147128 to BFA)
474 and the National Eye Institute (U10 EY023939 to JDK). This work was also made possible in
475 part by an Unrestricted Grant from Research to Prevent Blindness. We would also like to thank
476 Abbott for its donation of the m2000 RealTime molecular diagnostics system and consumables.
477

478 **Competing interest statement.** The authors have no competing interests to report. The
479 findings and conclusions in this article are those of the authors and do not necessarily represent
480 the official position of the Centers for Disease Control and Prevention. Use of trade names is for
481 identification only and does not imply endorsement by the Public Health Service or by the U.S.
482 Department of Health and Human Services.
483

484 **Data and availability.** The pre-specified statistical analysis plan will be made available on Open
485 Science Framework (<https://osf.io>). The main R packages used for this analysis were *automap*
486 (variograms) (91), *rgee* (Google Earth Engine) (92), *glmnet* (feature selection) (93), *spaMM*
487 (regression with spatial Gaussian process) (94), *s/3* (stacked ensemble) (95), and *blockCV*
488 (spatial cross-validation) (96). De-identified data and code to replicate this work will be made
489 available on Github (<https://github.com/ctedijanto/swift-spatial-prediction>). All analysis was
490 conducted in R Version 4.0.2 (“Taking Off Again”) (97).
491

492 **Author contributions:**

493 Conceptualization: CT, BFA
494 Data curation: CT, JDK
495 Formal analysis: CT
496 Funding acquisition: BFA, JDK
497 Investigation: CT, BFA
498 Methodology: CT, HJWS, BFA
499 Project administration: CT
500 Resources: SG, DLM, SDN
501 Software: CT
502 Supervision: TML, JDK, BFA
503 Validation: CT
504 Visualization: CT
505 Writing - original draft preparation: CT, BFA
506 Writing - review & editing: All authors

507 **REFERENCES**

508

- 509 1. H. R. Taylor, M. J. Burton, D. Haddad, S. West, H. Wright, Trachoma. *The Lancet* **384**,
- 510 2142–2152 (2014).
- 511 2. World Health Organization, “WHO Alliance for the Global Elimination of Trachoma by 2020:
- 512 progress report, 2019” (World Health Organization, 2020).
- 513 3. E. Sata, *et al.*, Twelve-Year Longitudinal Trends in Trachoma Prevalence among Children
- 514 Aged 1–9 Years in Amhara, Ethiopia, 2007–2019. *Am. J. Trop. Med. Hyg.* **104**, 1278–1289
- 515 (2021).
- 516 4. World Health Organization, “Validation of elimination of trachoma as a public health
- 517 problem” (World Health Organization, 2016) (April 6, 2021).
- 518 5. R. Bailey, C. Osmond, D. C. W. Mabey, H. C. Whittle, M. E. Ward, Analysis of the
- 519 Household Distribution of Trachoma in a Gambian Village Using a Monte Carlo Simulation
- 520 Procedure. *Int. J. Epidemiol.* **18**, 944–951 (1989).
- 521 6. A. T. Broman, K. Shum, B. Munoz, D. D. Duncan, S. K. West, Spatial Clustering of Ocular
- 522 Chlamydial Infection over Time following Treatment, among Households in a Village in
- 523 Tanzania. *Investig. Ophthalmology Vis. Sci.* **47**, 99 (2006).
- 524 7. M. Hägi, *et al.*, Active Trachoma among Children in Mali: Clustering and Environmental Risk
- 525 Factors. *PLoS Negl. Trop. Dis.* **4**, e583 (2010).
- 526 8. J. Yohannan, *et al.*, Geospatial Distribution and Clustering of *Chlamydia trachomatis* in
- 527 Communities Undergoing Mass Azithromycin Treatment. *Investig. Ophthalmology Vis. Sci.*
- 528 **55**, 4144 (2014).
- 529 9. A. Last, *et al.*, Spatial clustering of high load ocular *Chlamydia trachomatis* infection in
- 530 trachoma: a cross-sectional population-based study. *Pathog. Dis.* **75** (2017).
- 531 10. F. M. Altherr, *et al.*, Associations between Water, Sanitation and Hygiene (WASH) and
- 532 trachoma clustering at aggregate spatial scales, Amhara, Ethiopia. *Parasit. Vectors* **12**, 540
- 533 (2019).
- 534 11. S. F. Dowell, D. Blazes, S. Desmond-Hellmann, Four steps to precision public health.
- 535 *Nature* **540**, 189–191 (2016).
- 536 12. K. S. O’Brien, *et al.*, Antimicrobial resistance following mass azithromycin distribution for
- 537 trachoma: a systematic review. *Lancet Infect. Dis.* **19**, e14–e25 (2019).
- 538 13. S. Gebresillase, *et al.*, Inter-Rater Agreement between Trachoma Graders: Comparison of
- 539 Grades Given in Field Conditions versus Grades from Photographic Review. *Ophthalmic*
- 540 *Epidemiol.* **22**, 162–169 (2015).
- 541 14. E. B. Goodhew, *et al.*, CT694 and pgp3 as Serological Tools for Monitoring Trachoma
- 542 Programs. *PLoS Negl. Trop. Dis.* **6**, e1873 (2012).
- 543 15. E. B. Goodhew, *et al.*, Longitudinal analysis of antibody responses to trachoma antigens
- 544 before and after mass drug administration. *BMC Infect. Dis.* **14**, 3154 (2014).
- 545 16. B. F. Arnold, H. M. Scobie, J. W. Priest, P. J. Lammie, Integrated Serologic Surveillance of
- 546 Population Immunity and Disease Transmission. *Emerg. Infect. Dis.* **24**, 1188–1194 (2018).
- 547 17. F. Liu, *et al.*, Short-term Forecasting of the Prevalence of Trachoma: Expert Opinion,
- 548 Statistical Regression, versus Transmission Models. *PLoS Negl. Trop. Dis.* **9**, e0004000
- 549 (2015).
- 550 18. A. Pinsent, *et al.*, Probabilistic forecasts of trachoma transmission at the district level: A
- 551 statistical model comparison. *Epidemics* **18**, 48–55 (2017).
- 552 19. D. M. Wittberg, *et al.*, WASH Upgrades for Health in Amhara (WUHA): study protocol for a
- 553 cluster-randomised trial in Ethiopia. *BMJ Open* **11**, e039529 (2021).
- 554 20. World Health Organization, Trachoma (2020) (October 12, 2020).
- 555 21. J. D. Keenan, *et al.*, Slow resolution of clinically active trachoma following successful mass
- 556 antibiotic treatments. *Arch. Ophthalmol. Chic. Ill 1960* **129**, 512–513 (2011).

- 557 22. D. R. Roberts, *et al.*, Cross-validation strategies for data with temporal, spatial, hierarchical,
558 or phylogenetic structure. *Ecography* **40**, 913–929 (2017).
- 559 23. D. L. Martin, *et al.*, The use of serology for trachoma surveillance: Current status and
560 priorities for future investigation. *PLoS Negl. Trop. Dis.* **14**, e0008316 (2020).
- 561 24. M.-G. Basáñez, *et al.*, A Research Agenda for Helminth Diseases of Humans: Modelling for
562 Control and Elimination. *PLoS Negl. Trop. Dis.* **6**, e1548 (2012).
- 563 25. A. Pinsent, M. Gambhir, Improving our forecasts for trachoma elimination: What else do we
564 need to know? *PLoS Negl. Trop. Dis.* **11**, e0005378 (2017).
- 565 26. Y. Shen, *et al.*, Modeling Approaches to Predicting Persistent Hotspots in SCORE Studies
566 for Gaining Control of Schistosomiasis Mansonii in Kenya and Tanzania. *J. Infect. Dis.* **221**,
567 796–803 (2020).
- 568 27. E. S. Nightingale, *et al.*, A spatio-temporal approach to short-term prediction of visceral
569 leishmaniasis diagnoses in India. *PLoS Negl. Trop. Dis.* **14**, e0008422 (2020).
- 570 28. S. D. Nash, *et al.*, Population-Based Prevalence of Chlamydia trachomatis Infection and
571 Antibodies in four Districts with Varying Levels of Trachoma Endemicity in Amhara, Ethiopia.
572 *Am. J. Trop. Med. Hyg.* (2020) <https://doi.org/10.4269/ajtmh.20-0777> (November 7, 2020).
- 573 29. A. Cama, *et al.*, Prevalence of signs of trachoma, ocular Chlamydia trachomatis infection
574 and antibodies to Pgp3 in residents of Kiritimati Island, Kiribati. *PLoS Negl. Trop. Dis.* **11**,
575 e0005863 (2017).
- 576 30. R. Butcher, *et al.*, Ocular Chlamydia trachomatis infection, anti-Pgp3 antibodies and
577 conjunctival scarring in Vanuatu and Tarawa, Kiribati before antibiotic treatment for
578 trachoma. *J. Infect.* **80**, 454–461 (2020).
- 579 31. J. S. Kim, *et al.*, Community-level chlamydial serology for assessing trachoma elimination in
580 trachoma-endemic Niger. *PLoS Negl. Trop. Dis.* **13** (2019).
- 581 32. S. K. West, B. Munoz, H. Mkocho, C. A. Gaydos, T. C. Quinn, The effect of Mass Drug
582 Administration for trachoma on antibodies to Chlamydia trachomatis pgp3 in children. *Sci.*
583 *Rep.* **10**, 15225 (2020).
- 584 33. D. L. Martin, *et al.*, Serology for Trachoma Surveillance after Cessation of Mass Drug
585 Administration. *PLoS Negl. Trop. Dis.* **9**, e0003555 (2015).
- 586 34. S. K. West, *et al.*, Can We Use Antibodies to Chlamydia trachomatis as a Surveillance Tool
587 for National Trachoma Control Programs? Results from a District Survey. *PLoS Negl. Trop.*
588 *Dis.* **10**, e0004352 (2016).
- 589 35. S. J. Migchelsen, *et al.*, Serology reflects a decline in the prevalence of trachoma in two
590 regions of The Gambia. *Sci. Rep.* **7**, 15040 (2017).
- 591 36. S. K. West, *et al.*, Surveillance Surveys for Reemergent Trachoma in Formerly Endemic
592 Districts in Nepal From 2 to 10 Years After Mass Drug Administration Cessation. *JAMA*
593 *Ophthalmol.* **135**, 1141 (2017).
- 594 37. S. J. Migchelsen, *et al.*, Defining Seropositivity Thresholds for Use in Trachoma Elimination
595 Studies. *PLoS Negl. Trop. Dis.* **11**, e0005230 (2017).
- 596 38. J. D. Keenan, *et al.*, Clinical Activity and Polymerase Chain Reaction Evidence of
597 Chlamydial Infection after Repeated Mass Antibiotic Treatments for Trachoma. *Am. J. Trop.*
598 *Med. Hyg.* **82**, 482–487 (2010).
- 599 39. A. Amza, *et al.*, Community-level Association between Clinical Trachoma and Ocular
600 Chlamydia Infection after MASS Azithromycin Distribution in a Mesoendemic Region of
601 Niger. *Ophthalmic Epidemiol.* **26**, 231–237 (2019).
- 602 40. A. M. Ramadhani, T. Derrick, D. Macleod, M. J. Holland, M. J. Burton, The Relationship
603 between Active Trachoma and Ocular Chlamydia trachomatis Infection before and after
604 Mass Antibiotic Treatment. *PLoS Negl. Trop. Dis.* **10**, e0005080 (2016).
- 605 41. S. D. Nash, *et al.*, Ocular Chlamydia trachomatis Infection Under the Surgery, Antibiotics,
606 Facial Cleanliness, and Environmental Improvement Strategy in Amhara, Ethiopia, 2011–
607 2015. *Clin. Infect. Dis.* **67**, 1840–1846 (2018).

- 608 42. A. C. A. Clements, *et al.*, Targeting Trachoma Control through Risk Mapping: The Example
609 of Southern Sudan. *PLoS Negl. Trop. Dis.* **4**, e799 (2010).
- 610 43. S. R. Polack, *et al.*, The household distribution of trachoma in a Tanzanian village: an
611 application of GIS to the study of trachoma. *Trans. R. Soc. Trop. Med. Hyg.* **99**, 218–225
612 (2005).
- 613 44. P. Diggle, S. Lophaven, Bayesian Geostatistical Design. *Scand. J. Stat.* **33**, 53–64 (2006).
- 614 45. J.-F. Schémann, *et al.*, Risk factors for trachoma in Mali. *Int. J. Epidemiol.*, 194–201 (2002).
- 615 46. B. Bero, *et al.*, Prevalence of and Risk Factors for Trachoma in Oromia Regional State of
616 Ethiopia: Results of 79 Population-Based Prevalence Surveys Conducted with the Global
617 Trachoma Mapping Project. *Ophthalmic Epidemiol.* **23**, 392–405 (2016).
- 618 47. Y.-H. Hsieh, L. D. Bobo, T. C. Quinn, S. K. West, Risk Factors for Trachoma: 6-Year Follow-
619 up of Children Aged 1 and 2 Years. *Am. J. Epidemiol.* **152**, 204–211 (2000).
- 620 48. I. Phiri, *et al.*, The Burden of and Risk Factors for Trachoma in Selected Districts of
621 Zimbabwe: Results of 16 Population-Based Prevalence Surveys. *Ophthalmic Epidemiol.* **25**,
622 181–191 (2018).
- 623 49. W. Alemayehu, M. Melese, E. Fredlander, A. Worku, P. Courtright, Active trachoma in
624 children in central Ethiopia: association with altitude. *Trans. R. Soc. Trop. Med. Hyg.* **99**,
625 840–843 (2005).
- 626 50. R. F. Baggaley, *et al.*, Distance to water source and altitude in relation to active trachoma in
627 Rombo district, Tanzania. *Trop. Med. Int. Health TM IH* **11**, 220–227 (2006).
- 628 51. J. Ngondi, *et al.*, Risk factors for active trachoma in children and trichiasis in adults: a
629 household survey in Amhara Regional State, Ethiopia. *Trans. R. Soc. Trop. Med. Hyg.* **102**,
630 432–438 (2008).
- 631 52. E. M. Harding-Esch, *et al.*, Trachoma Prevalence and Associated Risk Factors in The
632 Gambia and Tanzania: Baseline Results of a Cluster Randomised Controlled Trial. *PLoS*
633 *Negl. Trop. Dis.* **4**, e861 (2010).
- 634 53. M. M. Mesfin, *et al.*, A Community-Based Trachoma Survey: Prevalence and Risk Factors in
635 the Tigray Region of Northern Ethiopia. *Ophthalmic Epidemiol.* **13**, 173–181 (2006).
- 636 54. C. Mpyet, B. D. Lass, H. B. Yahaya, A. W. Solomon, Prevalence of and Risk Factors for
637 Trachoma in Kano State, Nigeria. *PLOS ONE* **7**, e40421 (2012).
- 638 55. C. Mpyet, M. Goyol, C. Ogoshi, Personal and environmental risk factors for active trachoma
639 in children in Yobe state, north-eastern Nigeria. *Trop. Med. Int. Health* **15**, 168–172 (2010).
- 640 56. J.-F. Schémann, *et al.*, Trachoma, flies and environmental factors in Burkina Faso. *Trans.*
641 *R. Soc. Trop. Med. Hyg.* **97**, 63–68 (2003).
- 642 57. C. Vinke, S. Lonergan, Social and environmental risk factors for trachoma: a mixed methods
643 approach in the Kembata Zone of southern Ethiopia. *Can. J. Dev. Stud. Can. Déétudes Dév.*
644 **32**, 254–268 (2011).
- 645 58. T. Edwards, *et al.*, Risk factors for active trachoma and Chlamydia trachomatis infection in
646 rural Ethiopia after mass treatment with azithromycin. *Trop. Med. Int. Health* **13**, 556–565
647 (2008).
- 648 59. A. Abdou, *et al.*, Prevalence and risk factors for trachoma and ocular Chlamydia trachomatis
649 infection in Niger. *Br. J. Ophthalmol.* **91**, 13–17 (2007).
- 650 60. A. R. Last, *et al.*, Risk Factors for Active Trachoma and Ocular Chlamydia trachomatis
651 Infection in Treatment-Naïve Trachoma-Hyperendemic Communities of the Bijagós
652 Archipelago, Guinea Bissau. *PLoS Negl. Trop. Dis.* **8**, e2900 (2014).
- 653 61. X. Chen, W. D. Nordhaus, VIIRS Nighttime Lights in the Estimation of Cross-Sectional and
654 Time-Series GDP. *Remote Sens.* **11**, 1057 (2019).
- 655 62. B. Thylefors, C. R. Dawson, B. R. Jones, S. K. West, H. R. Taylor, A simple system for the
656 assessment of trachoma and its complications. *Bull. World Health Organ.* **65**, 477–483
657 (1987).
- 658 63. J. K. Møller, L. N. Pedersen, K. Persson, Comparison of the Abbott RealTime CT New

- 659 Formulation Assay with Two Other Commercial Assays for Detection of Wild-Type and New
660 Variant Strains of *Chlamydia trachomatis*. *J. Clin. Microbiol.* **48**, 440–443 (2010).
- 661 64. A. Cheng, Q. Qian, J. E. Kirby, Evaluation of the Abbott RealTime CT/NG Assay in
662 Comparison to the Roche Cobas Amplicor CT/NG Assay ν . *J. Clin. Microbiol.* **49**, 1294–
663 1300 (2011).
- 664 65. K. J. Ray, *et al.*, Estimating Community Prevalence of Ocular *Chlamydia trachomatis*
665 Infection using Pooled Polymerase Chain Reaction Testing. *Ophthalmic Epidemiol.* **21**, 86–
666 91 (2014).
- 667 66. S. C. Woodhall, *et al.*, Advancing the public health applications of *Chlamydia trachomatis*
668 serology. *Lancet Infect. Dis.* **18**, e399–e407 (2018).
- 669 67. Central Statistics Agency (CSA), Regional Bureau of Finance and Economic Development
670 (BoFED), *Ethiopia - Subnational Administrative Divisions* (2020) (November 3, 2020).
- 671 68. P. J. Diggle, P. J. Ribiero Jr, *Model-Based Geostatistics*, 1st ed (Springer Series in
672 Statistics, 2007).
- 673 69. C. Funk, *et al.*, The climate hazards infrared precipitation with stations—a new
674 environmental record for monitoring extremes. *Sci. Data* **2**, 150066 (2015).
- 675 70. J. T. Abatzoglou, S. Z. Dobrowski, S. A. Parks, K. C. Hegewisch, TerraClimate, a high-
676 resolution global dataset of monthly climate and climatic water balance from 1958–2015.
677 *Sci. Data* **5**, 170191 (2018).
- 678 71. K. Didan, *MOD13Q1 MODIS/Terra Vegetation Indices 16-Day L3 Global 250m SIN Grid*
679 *V006 [Data set]* (NASA EOSDIS Land Processes DAAC, 2015).
- 680 72. A. Jarvis, H. Reuter, A. Nelson, E. Guevara, *Hole-filled SRTM for the globe Version 4,*
681 *available from the CGIAR-CSI SRTM 90m* (2008).
- 682 73. J.-F. Pekel, A. Cottam, N. Gorelick, A. S. Belward, High-resolution mapping of global
683 surface water and its long-term changes. *Nature* **540**, 418–422 (2016).
- 684 74. T. G. Tiecke, *et al.*, Mapping the world population one building at a time. *ArXiv171205839*
685 *Cs* (2017) (October 1, 2020).
- 686 75. OpenStreetMap contributors, *Planet dump retrieved from <https://planet.osm.org>* (2017)
687 (March 5, 2021).
- 688 76. C. D. Elvidge, K. Baugh, M. Zhizhin, F. C. Hsu, T. Ghosh, VIIRS night-time lights. *Int. J.*
689 *Remote Sens.* **38**, 5860–5879 (2017).
- 690 77. D. J. Weiss, *et al.*, Global maps of travel time to healthcare facilities. *Nat. Med.* (2020)
691 <https://doi.org/10.1038/s41591-020-1059-1> (November 18, 2020).
- 692 78. N. Gorelick, *et al.*, Google Earth Engine: Planetary-scale geospatial analysis for everyone.
693 *Remote Sens. Environ.* (2017) <https://doi.org/10.1016/j.rse.2017.06.031>.
- 694 79. C. E. Rasmussen, C. K. I. Williams, *Gaussian processes for machine learning* (MIT Press,
695 2006).
- 696 80. L. Breiman, Stacked regressions. *Mach. Learn.* **24**, 49–64 (1996).
- 697 81. D. H. Wolpert, Stacked generalization. *Neural Netw.* **5**, 241–259 (1992).
- 698 82. M. J. van der Laan, E. C. Polley, A. E. Hubbard, Super Learner (2007) (November 25,
699 2020).
- 700 83. T. Hastie, R. Tibshirani, Generalized Additive Models. *Stat. Sci.* **1**, 297–310 (1986).
- 701 84. L. Breiman, Random Forests (September 19, 2020).
- 702 85. J. H. Friedman, Greedy Function Approximation: A Gradient Boosting Machine. *Ann. Stat.*
703 **29**, 1189–1232 (2001).
- 704 86. J. H. Friedman, Multivariate Adaptive Regression Splines. *Ann. Stat.* **19**, 1–67 (1991).
- 705 87. P. Ploton, *et al.*, Spatial validation reveals poor predictive performance of large-scale
706 ecological mapping models. *Nat. Commun.* **11**, 4540 (2020).
- 707 88. T. O. Kvålseth, Cautionary Note about R^2 . *Am. Stat.* **39**, 279–285 (1985).
- 708 89. A. E. Hubbard, S. Kherad-Pajouh, M. J. van der Laan, Statistical Inference for Data
709 Adaptive Target Parameters. *Int. J. Biostat.* **12**, 3–19 (2016).

- 710 90. D. Benkeser, *et al.*, A machine learning-based approach for estimating and testing
711 associations with multivariate outcomes. *Int. J. Biostat.* **0** (2020).
- 712 91. P. H. Hiemstra, E. J. Pebesma, C. J. W. Twenhofel, G. B. M. Heuvelink, Real-time
713 automatic interpolation of ambient gamma dose rates from the Dutch Radioactivity
714 Monitoring Network. *Comput. Geosci.* (2008).
- 715 92. C. Aybar, Q. Wu, L. Bautista, R. Yali, A. Barja, rgee: An R package for interacting with
716 Google Earth Engine. *J. Open Source Softw.* (2020).
- 717 93. J. Friedman, T. Hastie, R. Tibshirani, Regularization Paths for Generalized Linear Models
718 via Coordinate Descent. *J. Stat. Softw.* **33**, 1–22 (2010).
- 719 94. F. Rousset, J.-B. Ferdy, Testing environmental and genetic effects in the presence of spatial
720 autocorrelation. *Ecography* **37**, 781–790 (2014).
- 721 95. J. R. Coyle, N. S. Hejazi, I. Malenica, O. Sofrygin, *sl3: Modern Pipelines for Machine*
722 *Learning and Super Learning* (2021) <https://doi.org/10.5281/zenodo.1342293>.
- 723 96. R. Valavi, J. Elith, J. J. Lahoz-Monfort, G. Guillera-Arroita, blockCV: An r package for
724 generating spatially or environmentally separated folds for k-fold cross-validation of species
725 distribution models. *Methods Ecol. Evol.* **10**, 225–232 (2019).
- 726 97. R Core Team, *R: A language and environment for statistical computing.* (R Foundation for
727 Statistical Computing, 2020).